
Xieqiao Yan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3248348/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of Clinical Oncology, 2019, 37, 2987-2999.	1.6	126
2	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2021, 27, 43-51.	7.0	125
3	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	17.0	113
4	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. Clinical Cancer Research, 2017, 23, 6946-6957.	7.0	73
5	<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research, 2017, 23, 6120-6127.	7.0	71
6	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. European Journal of Cancer, 2016, 65, 156-163.	2.8	55
7	MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. Theranostics, 2019, 9, 945-960.	10.0	49
8	Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. British Journal of Ophthalmology, 2015, 99, 990-996.	3.9	46
9	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology, 2021, 39, 881-889.	1.6	37
10	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Annals of Surgical Oncology, 2018, 25, 2184-2192.	1.5	34
11	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer, 2018, 100, 1-7.	2.8	31
12	The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. Annals of Surgical Oncology, 2020, 27, 3478-3485.	1.5	29
13	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget, 2016, 7, 27044-27054.	1.8	28
14	Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thoracic Cancer, 2019, 10, 950-956.	1.9	27
15	Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. Oncology Research, 2019, 27, 495-501.	1.5	26
16	Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 515-515.	1.6	24
17	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
18	Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. European Journal of Cancer, 2021, 148, 297-306.	2.8	19

Xieqiao Yan

#	Article	IF	CITATIONS
19	Phase ⢠randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma Journal of Clinical Oncology, 2018, 36, 9589-9589.	1.6	18
20	Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report. Chinese Clinical Oncology, 2018, 7, 62-62.	1.2	16
21	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Frontiers in Oncology, 2020, 10, 546604.	2.8	15
22	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Annals of Surgical Oncology, 2022, 29, 5221-5234.	1.5	15
23	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4519-4519.	1.6	15
24	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. , 2022, 10, e004307.		13
25	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine, 2020, 55, 102755.	6.1	12
26	A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China Journal of Clinical Oncology, 2018, 36, 9539-9539.	1.6	12
27	Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4518-4518.	1.6	12
28	Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma Journal of Clinical Oncology, 2020, 38, 10007-10007.	1.6	11
29	RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study Journal of Clinical Oncology, 2021, 39, 4534-4534.	1.6	10
30	Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Frontiers in Immunology, 2021, 12, 691032.	4.8	10
31	A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma Journal of Clinical Oncology, 2020, 38, 10040-10040.	1.6	10
32	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e1-75.e8.	1.6	9
33	A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma Journal of Clinical Oncology, 2021, 39, 9512-9512.	1.6	9
34	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Frontiers in Oncology, 2021, 11, 720044.	2.8	9
35	A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma Journal of Clinical Oncology, 2018, 36, 9528-9528.	1.6	9
36	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Translational Oncology, 2018, 11, 1155-1159.	3.7	8

XIEQIAO YAN

#	Article	IF	CITATIONS
37	A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral Melanoma. Journal of Cancer, 2020, 11, 2945-2956.	2.5	8
38	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. Annals of Surgical Oncology, 2018, 25, 885-893.	1.5	7
39	Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. European Journal of Cancer, 2021, 156, 83-92.	2.8	7
40	Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations Journal of Clinical Oncology, 2019, 37, 9528-9528.	1.6	7
41	Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Translational Oncology, 2021, 14, 100949.	3.7	6
42	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials. Frontiers in Oncology, 2021, 11, 639085.	2.8	6
43	A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma Journal of Clinical Oncology, 2021, 39, 9570-9570.	1.6	5
44	Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations Journal of Clinical Oncology, 2015, 33, 9047-9047.	1.6	5
45	A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma Journal of Clinical Oncology, 2017, 35, 4575-4575.	1.6	5
46	A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma Journal of Clinical Oncology, 2020, 38, 10047-10047.	1.6	5
47	Prognostic value of HER2 expression levels for upper tract urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 557-557.	1.6	5
48	A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM) Journal of Clinical Oncology, 2022, 40, 9508-9508.	1.6	5
49	Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial Journal of Clinical Oncology, 2021, 39, 9573-9573.	1.6	4
50	Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma Journal of Clinical Oncology, 2017, 35, e21017-e21017.	1.6	4
51	OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment Journal of Clinical Oncology, 2017, 35, e21013-e21013.	1.6	4
52	Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 354-362.	1.9	4
53	Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2731-2740.	2.5	3
54	Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody Journal of Clinical Oncology, 2018, 36, e16505-e16505.	1.6	3

Xieqiao Yan

#	Article	IF	CITATIONS
55	Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma Journal of Clinical Oncology, 2021, 39, 9539-9539.	1.6	2
56	OrienX010 oncolytic viral therapy in phase â b trial of intralesional injection in unresected stage â¢c to ⣠acral melanoma patients in China Journal of Clinical Oncology, 2016, 34, e21001-e21001.	1.6	2
57	Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma Journal of Clinical Oncology, 2019, 37, e21050-e21050.	1.6	2
58	Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage ⣠melanoma with liver metastases Journal of Clinical Oncology, 2022, 40, 9551-9551.	1.6	2
59	Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial Journal of Clinical Oncology, 2022, 40, 9578-9578.	1.6	2
60	Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase Il trial Journal of Clinical Oncology, 2022, 40, 9512-9512.	1.6	2
61	Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma Journal of Clinical Oncology, 2021, 39, e18042-e18042.	1.6	1
62	Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma Journal of Clinical Oncology, 2015, 33, e20087-e20087.	1.6	1
63	A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors Journal of Clinical Oncology, 2017, 35, 3067-3067.	1.6	1
64	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710) Journal of Clinical Oncology, 2019, 37, 9521-9521.	1.6	1
65	Mucosal melanoma of the female genital tract: Operation modalities Journal of Clinical Oncology, 2019, 37, e21060-e21060.	1.6	1
66	IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study Journal of Clinical Oncology, 2020, 38, e15111-e15111.	1.6	1
67	Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy Journal of Clinical Oncology, 2020, 38, e22043-e22043.	1.6	1
68	Surgical Outcomes of Vaginal or Cervical Melanoma. Frontiers in Surgery, 2021, 8, 771160.	1.4	1
69	Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 524-524.	1.6	1
70	Phase lb study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4563-4563.	1.6	1
71	Clinicopathologic features of Xp11.2 translocation renal cell carcinoma and its response to target therapy Journal of Clinical Oncology, 2021, 39, e16559-e16559.	1.6	0
72	Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib Journal of Clinical Oncology, 2015, 33, 481-481.	1.6	0

XIEQIAO YAN

#	Article	IF	CITATIONS
73	A phase II study of everolimus for advanced melanoma patients with mTOR mutations Journal of Clinical Oncology, 2015, 33, e20007-e20007.	1.6	0
74	The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma Journal of Clinical Oncology, 2015, 33, e20043-e20043.	1.6	0
75	Clinical presentation, systemic therapy and prognosis of mucosal melanoma, a study of 463 consecutive cases Journal of Clinical Oncology, 2015, 33, e20036-e20036.	1.6	Ο
76	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783) Journal of Clinical Oncology, 2015, 33, e15591-e15591.	1.6	0
77	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma Journal of Clinical Oncology, 2015, 33, e20076-e20076.	1.6	0
78	Comparison of clinical presentation and prognosis between acral cutaneous melanoma and non-acral cutaneous melanoma Journal of Clinical Oncology, 2015, 33, e20008-e20008.	1.6	0
79	The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma Journal of Clinical Oncology, 2016, 34, 444-444.	1.6	0
80	A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710) Journal of Clinical Oncology, 2016, 34, e21043-e21043.	1.6	0
81	A prospective multicenter phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma (NCT01762150) Journal of Clinical Oncology, 2016, 34, 4559-4559.	1.6	0
82	Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors Journal of Clinical Oncology, 2017, 35, e21055-e21055.	1.6	0
83	Multivariate analysis of prognostic factors among 706 mucosal melanoma patients Journal of Clinical Oncology, 2017, 35, 9569-9569.	1.6	0
84	A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy Journal of Clinical Oncology, 2019, 37, e14081-e14081.	1.6	0
85	Mucosal melanoma staging and classification: Firstly established Journal of Clinical Oncology, 2019, 37, e21008-e21008.	1.6	0
86	Postoperative radiotherapy in resected sinonasal mucosal melanoma Journal of Clinical Oncology, 2019, 37, e21059-e21059.	1.6	0
87	Continuous intravenous infusion Rh-endostatin in combination with dacarbazine and cisplatin as the first-line therapy for metastatic melanoma Journal of Clinical Oncology, 2019, 37, e21007-e21007.	1.6	0
88	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	3.5	0
89	Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma Journal of Clinical Oncology, 2022, 40, 341-341.	1.6	0
90	Clinical characteristics of patients with collecting duct carcinoma Journal of Clinical Oncology, 2022, 40, 297-297.	1.6	0

XIEQIAO YAN

#	Article	IF	CITATIONS
91	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. Annals of Surgical Oncology, 2022, , .	1.5	0
92	The association of Ki67 level and adjuvant treatment options in mucosal melanoma Journal of Clinical Oncology, 2022, 40, e21582-e21582.	1.6	0
93	Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma Journal of Clinical Oncology, 2022, 40, e21543-e21543.	1.6	Ο